Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain. The procedure typically takes approximately one hour in an outpatient surgery center.
Based on existing data, patients usually experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.
Source: Relievant Medsystems
Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using...
Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain. The procedure typically takes approximately one hour in an outpatient surgery center.
Based on existing data, patients usually experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.
Source: Relievant Medsystems
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.